Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    CAMMS03409
Show Display Options
Rank Status Study
1 Recruiting Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: alemtuzumab GZ402673
2 Active, not recruiting An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Biological: alemtuzumab

Indicates status has not been verified in more than two years